SignaLife is a technology company developing lifesaving AI optic sensors for medical and well-being use. The company’s products are designed to provide non-invasive and continuous pH and Blood Gases for patients hospitalized in the ICU and NICU (neonatal ICU). Initial results from the company’s first in human trial in Assuta Ashdod ICU, showing high accuracy in testing pH, pCO2, Bi-carbonate (HCO3) and lactate. First baby in the 2nd clinical trial in Sheba Medical Center’s NICU was recruited during April 2025 with promising pH results. SignaLife’s solutions address the need for non-invasive, reliable measurements, reducing infection risk, minimizing blood draws, and supporting better treatment decisions.